ACIP votes to expand recommendation for Pfizer’s RSV vaccine ABRYSVO to include adults aged 50 – 59 at increased risk of disease

Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74

Asahi Kasei establishes Asahi Kasei Life Science to drive its bioprocess businesses

Asahi Kasei Life Science covers a broad range of bioprocess products and services

Asahi Kasei Life Science begins operation

Being a premium partner for pharmaceutical companies by contributing to safety and productivity of pharmaceutical manufacture

Zydus Lifesciences launches ANVIMO

ANVIMO will be available in dosages of 240 mg and 480 mg

FDA grants EUA to Aptitude’s Covid/flu multiplex test for OTC use

Moderna announces updates on pandemic influenza program

The project will provide additional support for late-stage development and licensure of pre-pandemic mRNA-based vaccines

ProBioGen expands protein and viral manufacturing to drive continued growth

This strategic move aims to address the increasing global demand for biologics, enhancing ProBioGen's ability to support partners from cell line development t

HMPV update: States advised to strengthen awareness among masses regarding preventive measures

Data from IDSP does not indicate any unusual rise in ILI/SARI cases anywhere in the country

ICMR detects two cases of HMPV in Karnataka through routine surveillance

ICMR will continue to track trends in HMPV circulation throughout the year

Merck announces FDA acceptance of biologics license application for Clesrovimab

An investigational long-acting monoclonal antibody designed to protect infants from RSV disease during their first RSV season